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Proopiomelanocortin (POMC) is a 31 kDa prohormone
that is processed to various bioactive peptides, including
adrenocorticotropin (ACTH), melanotropins (a, b, g-
MSH), lipotropins, and endorphins. POMC is expressed
not only in the pituitary gland but also in a variety of
nonpituitary organs and tumors, including melanomas.
We previously showed that normal human melanocytes
produce and secrete a-MSH and ACTH, and further-
more, that advanced melanoma cells generally produce
higher amounts of POMC peptides that correlate with
tumor progression. To elucidate the mechanism of this
upregulation, the expression of genes encoding cortico-
tropin-releasing hormone (CRH) and its receptor, CRH-
R, as well as POMC and the MSH receptor (MC1-R),
was evaluated by reverse transcriptase-polymerase chain
α -Melanocyte-stimulating hormone (MSH) has beenreported to stimulate proliferation of melanoma cells andto enhance their metastatic behavior in an autocrine orparacrine manner in mouse models (Sheppard et al, 1984;
Bregman et al, 1985; Bennett et al, 1986). In a number of in vivo
studies, extracts of metastatic melanomas were shown to contain α-
MSH-like bioactive peptides as well as active MSH receptors (Ghanem
et al, 1989, 1992; Tatro et al, 1990). In fact, several reports have
suggested that MSH and/or its secondary messengers may be involved
in melanoma metastasis (Sheppard et al, 1984; Bennett et al, 1986;
Lunec et al, 1990, 1992; Zubair et al, 1992). To evaluate whether the
expression of proopiomelanocortin (POMC) products is correlated with
melanoma progression, the presence of α-MSH, adrenocorticotropic
hormone (ACTH), and β-endorphin was examined immunohisto-
chemically in benign and malignant melanocytic lesions in our laborat-
ory (Nagahama et al, 1998). That study indicated that higher amounts
of POMC peptides might be produced in correlation with tumor
progression. We and others have shown that expression of POMC
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reaction using cultured human melanoma cells, nevus
cells, and normal melanocytes. Our results show that all
melanocytic cells express CRH, CRH-R, POMC, and
MC1-R, with highest intensities in melanoma cells.
Furthermore, immunohistochemistry shows that CRH
as well as POMC is strongly expressed in advanced
melanomas, such as vertically growing lesions of acral
lentiginous, nodular and metastatic melanomas, in
contrast to negative expression in nevus cells. These
results indicate that tumor progression accentuates
CRH, CRH-R, and POMC expression by melanoma
cells. Key words: immunohistochemistry/RT-PCR. Journal
of Investigative Dermatology Symposium Proceedings 4:105–
109, 1999
peptides is upregulated in cultured keratinocytes and melanocytes by
exposure to interleukin-1 (IL-1), dibutyryl cyclic AMP (dbcAMP),
12-O-tetradecanoylphorbol-13-acetate (TPA), and ultraviolet B (UVB)
(Schauer et al, 1994; Chakraborty et al, 1996; Funasaka et al, 1998).
In the hypothalamus-pituitary-axis, induction of corticotropin-
releasing hormone (CRH) production activates the CRH-receptor
(CRH-R) and induces production and secretion of POMC. The CRH
gene is also expressed in extracranial tissues, including human skin
(Slominski et al, 1995, 1996, 1998; Slominski and Mihm, 1996).
Expression of CRH and CRH-R type 1 mRNA has been detected
in cultured human melanocytes and in melanoma cells, as well as in
nevus tissues (Slominski et al, 1995); however, a comparative study
using various types of cultured cells has not yet been done.
In this study, we examined whether the CRH/CRH-R/POMC
loop in the skin is involved in melanoma progression, using semi-
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR),
with cultured melanocytic cells, including normal human melanocytes,
junctional and dermal nevus cells, and melanoma cells. Furthermore,
the localization of CRH expression in melanoma tissues was studied
by immunohistochemistry in relation to tumor progression.
MATERIALS AND METHODS
Cell culture Normal human melanocytes were established from foreskins in
culture and maintained in Ham’s F-10 medium supplemented with 5% fetal
calf serum, 85 nM TPA, 0.1 mM IBMX, 1.0 mM insulin, and 40 µg protein/
ml pituitary extract (Funasaka et al, 1992). Nevus samples were incubated
overnight at room temperature in 0.25% trypsin, 0.25% EDTA in phosphate-
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buffered saline (PBS) without Ca11 and Mg11. After this initial incubation,
the epidermis was removed from the dermis, and the dermal surface was gently
scraped to obtain junctional cells. Dermal components were minced and put
on gelatin-coated dishes supplied with small amounts of medium. Cells obtained
from junctional and dermal components of each lesion were then seeded
separately in Ham’s F-10 medium plus supplements as described above for the
melanocyte culture (Ohashi et al, 1996). These nevus cells are highly pigmented
and grow rapidly in TPA-containing medium compared with epidermal
melanocytes (Halaban et al, 1986). Six metastatic melanoma cell lines were used
in this study: G361, MEWO, P22, P39 (obtained from the Japanese Cancer
Research Resources Bank, Tokyo, Japan), YP-MEL (Nagashima et al, 1994),
and A101D (Kameyama et al, 1986). All melanoma lines were grown in culture
in MEM medium plus 10% fetal calf serum.
RT-PCR Total RNA was extracted using ISOGEN (Nippon Gene, Toyama,
Japan) following the manufacturer’s instructions. For RT-PCR assays, 5 µg of
total RNA was reverse transcribed using oligo (dT) as primers and Moloney
Murine Leukemia Virus Reverse Transcriptase (GIBCO-BRL, Life Techno-
logies, Grand Island, NY). For quantitative PCR, a control gene, β-actin, was
amplified using primers and conditions described by Lahm et al (1995). Only
samples that were proven to be free from DNA contamination, using PCR
amplification with β-actin primers without prior RT, were used for these
experiments. Oligonucleotides used were (i) 59-CAC CCT CAG CCC TTG
GAT TTC-39 (sense) and 59-GCC CTG GCC ATT TCC AAG AC-39
(antisense) for CRH (Slominski et al, 1995); (ii) 59-GCC CTG CCC TGC
CTT TTT CTA-39 (sense) and 59-GCT CAT GGT TAG CTG GAC CA-39
(antisense) for CRH-R (Slominski et al, 1995); (iii) 59-GAG GGC AAG CGC
TCC TAC TCC-39 (sense) and 59-GGG GCC CTC GTC CTT CTT CTC-
39 (antisense) for POMC (Chakraborty et al, 1996); (iv) 59-GCC ACC ATG
CCA AGA ACC-39 (sense) and 59-ATA GCC AGG AAG AAG ACC A-39
(antisense) for MC1-R (Bhardwaj et al, 1997), and (v) 59-GGC ATC GTG
ATG GAC TCC G-39 (sense) and 59-GTC GGA AGG TGG ACA GCG A-
39 (antisense) for β-actin (Lahm et al, 1995).
Samples for PCR contained 5 µl of the cDNA corresponding to 0.5 µg of
total RNA, 25 units AmpliTaq Gold DNA polymerase (Perkin-Elmer, Branch-
burg, NJ) per ml, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
dATP, dCTP, dGTP, dTTP (200 µmol each), and 100 pmol each of the
appropriate sense and antisense primers. The final reaction volume was 50 µl.
Samples were heated for 9 min at 95°C and then amplified for 45 cycles at
94°C, 55°C (for CRH, CRH-R, POMC, and β-actin) or 51°C (for MC1-
R), and 72°C (45 s each). After a final extension at 72°C for 10 min, 10 µl of
the PCR product was separated in 1.5% agarose gels, stained with ethidium
bromide, and photographed under UV.
Tissue specimens and immunohistologic staining Four cases of superficial
spreading melanoma, nine cases of acral lentiginous melanoma, five cases of
nodular melanoma, 12 cases of metastatic melanoma, eight cases of benign nevi,
and four cases of normal skin used as samples were obtained from surgical
specimens. Tissues were fixed in paraformaldehyde, embedded in paraffin, and
sectioned. Deparaffinized sections were incubated with a polyclonal rabbit anti-
CRH antibody (Auchus et al, 1994) followed by the avidin-biotin-peroxidase
detection system (Dako LSAB Kit, Dako, Kyoto, Japan), with 3-amino-9-
ethylcarbazole as the chromogen. Normal rabbit serum (Antibodies Inc., Davis,
CA) was used instead of CRH antibody as a negative control.
RESULTS
CRH, CRH-R, POMC, and MC1-R mRNA expression Semi-
quantitative RT-PCR showed that mRNA expression of CRH
(413 bp), CRH-R (334 bp), POMC (260 bp), and MC1-R (416 bp)
was detectable in all melanoma cells, nevus cells, and melanocytes
examined (Fig 1). Sizes of PCR products were equal to those
predicted from primer sequences and in agreement with previous
reports (Slominski et al, 1995; Chakraborty et al, 1996; Bhardwaj et al,
1997). The concentration of amplified fragments of the β-actin
transcript was used as an internal control.
All melanoma cells examined showed stronger expression of CRH,
POMC, and MC1-R than nevus cells and normal melanocytes, and
four of six melanoma cell lines also showed higher expression of
CRH-R (Fig 1, Table I). There was essentially no difference in
intensity of expression of CRH, CRH-R, POMC, and MC1-R
between junctional and dermal nevus cells. In the case of normal
human melanocytes, expression of POMC and MC1-R was weaker
than in nevus cells, although there was no difference in the expression
intensity of CRH or CRH-R between nevus cells and melanocytes.
Figure 1. RT-PCR study of gene expression in cultured melanocytic
cells. Six melanoma cell lines (G361, MEWO, P22, P39, A101D, and YP-
MEL), nevus cells derived from junctional and dermal lesions of congenital
nevus, and normal human epidermal melanocytes were used. RT-PCR for
CRH, CRH-R, POMC, MC1-R, and β-actin was performed as described in
the Materials and Methods. The left lane is a DNA size marker of 1353, 1078,
872, 603, 310, 281/271, 234, 194, 118, and 72 bp.
Table I. Summary of gene expression by melanocytic cellsa
Culture cells CRH CRH-R POMC MC1-R
Melanoma
G361 11 1 11 11
MEWO 11 11 11 11
P22 11 111 11 11
P39 11 111 11 11
A101D 11 6 111 11
YP-MEL 11 111 111 1
Nevus cells
Junction (NCN-J) 1 1 1 1
Dermal (NCN-D) 1 1 1 1
Melanocytes (MC) 1 1 6 6
aThis table summarizes the expression patterns of transcripts for CRH, CRH-R, POMC,
and MCI-R as shown in Fig 1. 6, weakly expressed; 1, moderately expressed; 11,
strongly expressed; 111, very strongly expressed.
Expression of CRH peptides in skin specimens In normal skin,
CRH was expressed in differentiated keratinocytes of the uppermost
portion of the Malphigian layer and not in the epidermal melanocytes
(Fig 2A), similar to the staining pattern of POMC peptides we
previously reported (Nagahama et al, 1998). Junctional and dermal
nevus cells also showed no detectable staining of CRH (Table II), all
of which was compatible with the results indicating weaker expression
of the CRH gene in nevus cells and melanocytes detected by RT-PCR.
In melanoma tissues, CRH-positive cells were recognized. In superficial
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Figure 2. Expression of CRH in melanoma tissues. Melanoma tissues
were obtained from surgical specimens, fixed in paraformaldehyde, embedded
in paraffin, and sectioned. Deparaffinized sections were incubated with the
rabbit antiserum against r/hCRH, followed by the avidin-biotin-peroxidase
detection system, with 3-amino-9-ethyl-carbazole as chromogen. All acral
lentiginous melanoma samples examined showed positive immunostaining with
stronger staining in vertically growing invading cells (A, C) than in horizontally
growing cells (A, B). Part (A) is low magnification, and (B, C) are in higher
magnification. Arrows indicate the localization of positive melanoma cells. Scale
bars: 100 µm.
spreading melanomas, only one of the four cases showed weakly
positive staining. All nine acral lentiginous melanoma cases showed
positive melanoma cells, and most of the strongly CRH-positive cells
were found in vertically growing portions, in contrast with rather
weak staining for CRH in horizontally growing cells (Fig 2). In
nodular and metastatic melanoma tissues, the percentage of CRH-
positive melanoma cells was more than 20%, and the staining intensity
was rather strong (Table II). No specific staining was seen in control
Table II. Immunoreactivity of corticotropin-releasing
hormone (CRH) in nevi and melanomasa
– 1 11 111
Tissue
Common nevi 8 0 0 0
Superficail spreading melanoma 3 1 0 0
Acral lentiginous melanoma 0 5 3 1bc
Nodular melanoma 1 1 2c 1c
Metastatic melanoma 1 5 3c 3c
a–, negative; 1, weakly positive; 11, strongly positive; 111, very strongly positive.
bMost of the positive cells were found in vertically growing portions.
c.20% of the melanoma cells showed positive staining.
sections when normal rabbit serum was used instead of CRH-specific
antibodies (not shown).
DISCUSSION
In this study, we have shown that melanoma cells express CRH and
CRH-R mRNA in addition to transcripts for POMC and MC1-R.
The in vivo results provided evidence that vertical-growth (advanced)
melanoma cells strongly expressed CRH peptides compared with
horizontal-growth (less invasive) cells. By immunohistochemistry, we
could not detect CRH expression in normal epidermal melanocytes
or in nevus cells. It is possible that the negative staining was due to
the rather low sensitivity of the immunohistochemical method. Our
results made it clear that all melanocytic lineage cells in different
malignant stages expressed CRH mRNA and peptides with accentuated
expression during tumor progression.
CRH, a 41-amino acid peptide, is synthesized in the hypothalamus
(Vale et al, 1983; Antoni, 1986). CRH is also produced at several
extrahypothalamic sites, including most peripheral reproductive tissues
(Petrusz et al, 1983, 1984; Suda et al, 1984; Usui et al, 1988; Fabbri
et al, 1990; Orth, 1992; Mastorakos et al, 1993, 1994; Scopa et al,
1994; Makrigiannakis et al, 1995). The latter suggests that CRH, in
addition to its well-established central antireproductive effect
(Petraglia et al, 1987; Rivier et al, 1986), may also exert an effect at
the peripheral level. Slominski et al (1998) proposed that molecular
elements of the hypothalamus-pituitary axis, including CRH and
POMC peptides, operate locally in the skin as a part of an organized
response to stress. Both CRH and CRH-R are expressed in several
peripheral tissues, including adrenals, gonads, placenta, the gastrointesti-
nal system, pancreas, and immune cells (Thompson et al, 1987; Owens
and Nemeroff, 1991; Orth, 1992; Vamvakopoulos and Chrousos, 1994;
Zoumakis et al, 1997), implying a paracrine mode of action. Similarly,
cutaneous CRH could locally regulate several components in the skin,
such as the immune, vascular, adnexal, and perhaps epithelial and
melanocytic systems. This could be accomplished directly, via inter-
action with specific receptors, or indirectly, via stimulation of local
production of ACTH, MSH, and β-endorphin (Slominski et al, 1998).
Locally produced POMC peptides are known to regulate skin functions.
Of particular interest for melanoma biology are regulation of the
differentiated phenotype and proliferation by MSH and ACTH
(Lunec et al, 1990) and immunomodulatory functions of β-endorphins,
corticotropins, and melanotropins (Blalock, 1989; Bhardwaj et al,
1997). It is generally accepted that the malignant behavior of solid
tumors results from complex multidirectional interactions between
different cell populations, including cells of the immune system (Hahne
et al, 1996). Therefore, CRH/POMC expression in melanomas could
imply the existence of autoregulatory loops governing the phenotype
and malignancy of melanomas, which would involve autocrine and
paracrine regulation as well as cross-talk between melanoma cells and
cells of the immune system.
High levels of expression of CRH peptides might result in higher
expression of POMC peptides, thus endowing melanoma cells with
growth and metastatic ability. To elucidate whether there is co-
localization of melanoma cells with high expression of CRH and
POMC peptides, we further extended the immunohistochemical study.
In some advanced melanomas, there was coincidence of CRH- and
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POMC-expressing melanoma cells; however, in others, POMC was
highly expressed without concomitantly high CRH expression (Sato
et al, manuscript in preparation). This is compatible with our preliminary
results that CRH at 10–8 M stimulates POMC mRNA expression in
two of five melanoma cell lines examined (our unpublished data). This
suggests that some POMC-producing melanoma cells are regulated by
CRH for POMC expression, whereas others are not and might be
regulated by other factors such as IL-1, Ca11, or cAMP inducers
(Schauer et al, 1994; Ruzicka and Akil, 1995; Chakraborty et al, 1996).
Coexpression of CRH and POMC in melanoma cells suggests that
melanoma-derived CRH may have autocrine or paracrine effects on
POMC-derived peptide secretion in melanomas, as is the case for
other peripheral tissues, such as the placenta and testes (Makrigiannakis
et al, 1995). Although advanced melanoma cells showed strong expres-
sion of CRH and POMC peptides, none of those patients presented
obvious clinical manifestations of hyperadrenocorticism, suggesting that
even if the tumors had had hypothalamic hormones, they were not
stimulating other target tissues. This phenomenon has also been
observed in other tumors such as breast tumors (Ciocca et al, 1990).
MSH has already been reported to enhance the proliferation and
metastatic ability of melanoma cells (Sheppard et al, 1984; Bregman
et al, 1985; Bennett et al, 1986). The action of CRH on melanoma
cells, however, was not previously known. In our recent study, CRH
at 10–8 M upregulated DNA synthesis by melanoma cells in all five
melanoma cell lines examined, and furthermore, a CRH antagonist at
10–8 M inhibited DNA synthesis of two of the five melanoma cell
lines (Sato et al, manuscript in preparation). This suggests that CRH
could stimulate melanoma growth, although it needs to be elucidated
whether CRH acts directly or indirectly via the POMC/MC1-R loop.
In endometrial cells, CRH gene expression is reported to be under
the negative control of estrogens and glucocorticoids and under the
positive control of prostaglandin E2 (Makrigiannakis et al, 1996). The
mechanisms of upregulation of CRH gene expression in melanomas
remain to be clarified.
In summary, we have now demonstrated that normal human
melanocytes, nevus cells, and melanoma cells express CRH and
CRH-R, with the highest intensity in melanoma cells. This is
compatible with the in vivo results demonstrating that CRH peptides
are strongly expressed in vertically growing melanoma lesions compared
with horizontally growing cells or nevus cells. We therefore suggest
that tumor progression might endow accentuated CRH/CRH-R/
POMC expression in some melanomas.
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